Tirzepatide

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The 39-amino-acid backbone is engineered around the native GIP sequence with substitutions that confer cross-reactivity at the GLP-1 receptor, and a C20 fatty diacid moiety attached at Lys20 mediates reversible albumin binding to extend half-life into the once-weekly range.

At the GLP-1 receptor, tirzepatide drives glucose-dependent insulin secretion from pancreatic β-cells, suppresses glucagon release, slows gastric emptying, and acts on hypothalamic centers regulating satiety. At the GIP receptor, the compound potentiates insulin response in the post-prandial state and is hypothesized to modulate adipocyte function and lipid handling — the GIP arm is the principal pharmacological distinction from selective GLP-1 agonists such as semaglutide.

Receptor-binding studies report tirzepatide as a biased agonist at GLP-1R, with cAMP signaling preserved and β-arrestin recruitment reduced relative to native GLP-1. This signaling bias is the leading mechanistic hypothesis for the comparatively lower receptor desensitization observed in preclinical models.

Research Applications

• Comparative receptor-pharmacology studies of dual incretin agonism versus selective GLP-1 agonism.
• Investigations of GIP receptor contribution to weight regulation, lipid metabolism, and adipose tissue function.
• Long-duration pharmacokinetic studies using fatty-acid acylation for albumin-anchored half-life extension.
• Translational research comparing tirzepatide pharmacology to next-generation triple agonists such as retatrutide.